Skip to product content

ACTIVE PHARMACEUTICAL INGREDIENT

Upadacitinib API

Research Upadacitinib API through FDA DMF and China CDE records. Compare reported companies, check registration status and confirm the chemical form before preparing a sourcing or dossier review.

Complete data requires an active subscription. Already subscribed? Sign in to access your data.

This Upadacitinib profile uses the anhydrous free-base reference identity, CAS 1310726-60-3. Explicit hemihydrate and intermediate subjects are excluded. Records are selected by reported substance name; neither source supplies a CAS field to verify the chemical form of every filing.

Upadacitinib registration data overview

Upadacitinib registry coverage: 9 FDA API DMF entries and 30 CDE API registrations selected by substance name. Browse free samples, then subscribe to search, filter and export the complete available Upadacitinib records.

0 documented company-name correspondences

The registries have different snapshot dates and status definitions. Counts describe records, not qualified suppliers. Company fields retain their original wording, including repeated parties. No cross-registry company-name correspondences are documented for this profile.

Personal API data subscription

$19.00 per month

$149.00 per year

Billed $149.00 every year

Upadacitinib coverage: 9 FDA DMF records and 30 CDE registrations. Free CSV samples contain the preview rows; a subscription opens the complete available records.

Subscription benefits and CSV samples
  • Complete available registry records
  • Search and status filters
  • Documented company-name correspondences
  • CSV exports with sources

One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.

Reported companies in Upadacitinib registry records

Use the Upadacitinib registry tables below to inspect original holder and company fields. No cross-registry company-name correspondences are documented. Similar names, translations or membership of the same group do not verify an identical legal entity or manufacturing site.

Free previewShowing 0 sample records of 0.

0 company-name correspondences

No exact company-name correspondences are documented for these snapshots.

Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.

Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.

US REGULATORY RECORDS

Upadacitinib FDA Drug Master Files

Inspect Upadacitinib DMF holders, reported subjects, initial submission dates and activity codes. Compare the original fields before requesting dossier access. An active filing does not establish a qualified manufacturing site or an available batch.

API DMF records: 9. Distinct reported holder names: 9.

9Active (A)

0Inactive (I)

A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.

Free previewShowing 3 sample records of 9.

  • CURIA SPAIN SAUDMF number 37149Active (A)Record details
    DMF number
    37149
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    2022-06-01
    Reported holder
    CURIA SPAIN SAU
    Reported subject
    UPADACITINIB
  • APITORIA PHARMA PRIVATE LTDDMF number 38095Active (A)Record details
    DMF number
    38095
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    2023-02-22
    Reported holder
    APITORIA PHARMA PRIVATE LTD
    Reported subject
    UPADACITINIB
  • MSN LABORATORIES PRIVATE LTDDMF number 38153Active (A)Record details
    DMF number
    38153
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    2023-03-26
    Reported holder
    MSN LABORATORIES PRIVATE LTD
    Reported subject
    UPADACITINIB

Free preview

More records available with a subscription: 6.

Inclusion criteria
  • Selected Upadacitinib Type II records: 9. Subjects match UPADACITINIB after trimming leading and trailing whitespace for selection only. The original subject is retained, including the trailing space in DMF 40344.
  • Excludes three explicitly named Upadacitinib intermediates and six hemihydrate subjects. Type II alone does not distinguish a drug substance from an intermediate. An unqualified name does not independently confirm CAS 1310726-60-3 or an anhydrous solid-state form for each filing.
  • All six source fields and original row order are retained. Only Excel submission dates are converted to ISO format. Activity status reflects the June 30, 2026 cutoff, not a live lookup.

CHINA REGULATORY RECORDS

Upadacitinib NMPA CDE registrations

Inspect Upadacitinib registration numbers, original Chinese company names, packaging and review status. Expand a record to read all eleven source columns. Separate registration numbers remain separate records even when the same enterprise is reported.

30 name-selected API registration records

9Approved or qualifying prior approval (A)

21Technical review not passed or unlinked (I)

CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.

Free previewShowing 3 sample records of 30.

  • 天地恒一制药股份有限公司Registration number Y20230000796Approved or qualifying prior approval (A)Record details
    Registration number
    Y20230000796
    Reported substance name
    乌帕替尼
    Reported company names
    天地恒一制药股份有限公司
    Reported company addresses
    湖南省长沙国家生物产业基地康天路109号
    Reported product origin
    Domestic production (境内生产)
    Reported packaging
    0.5kg/袋×1袋/桶;1.0kg/袋×1袋/桶;2.0kg/袋×1袋/桶;3.0kg/袋×1袋/桶
    Reported specification
    Not provided by source
    Record updated
    2026-06-23
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2029-11-25
    Source remarks
    Not provided by source
  • 四川国为制药有限公司Registration number Y20230001341Approved or qualifying prior approval (A)Record details
    Registration number
    Y20230001341
    Reported substance name
    乌帕替尼
    Reported company names
    四川国为制药有限公司
    Reported company addresses
    眉山市经济开发区新区
    Reported product origin
    Domestic production (境内生产)
    Reported packaging
    1kg/袋、2kg/袋
    Reported specification
    Not provided by source
    Record updated
    2025-03-19
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2030-03-18
    Source remarks
    Not provided by source
  • 浙江华海药业股份有限公司Registration number Y20240000970Approved or qualifying prior approval (A)Record details
    Registration number
    Y20240000970
    Reported substance name
    乌帕替尼
    Reported company names
    浙江华海药业股份有限公司
    Reported company addresses
    浙江省临海市杜桥镇川南
    Reported product origin
    Domestic production (境内生产)
    Reported packaging
    25kg/桶,20kg/桶,15kg/桶,10kg/桶,5kg/桶,2kg/桶,1kg/桶,0.5kg/桶,0.2kg/桶
    Reported specification
    Not provided by source
    Record updated
    2026-04-03
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2031-04-02
    Source remarks
    Not provided by source

Free preview

More records available with a subscription: 27.

Inclusion criteria
  • Includes 30 registrations named exactly 乌帕替尼, associated with this Upadacitinib reference profile. The CSV has no CAS or dedicated hydrate field; its name alone cannot verify CAS 1310726-60-3 or exclude an undisclosed hydrated form.
  • All eleven source columns, original row order and reported company fields are retained. Multiple registrations for one company are preserved. No cross-registry legal-entity or manufacturing-site match is inferred from English and Chinese names.
  • Blank fields remain blank and display as Not provided by source. Packaging, dates and review codes describe the October 5, 2026 snapshot; no missing specification or current supply status is inferred.

Upadacitinib chemical identity

Upadacitinib, also known as ABT-494, is identified here by the anhydrous free-base CAS 1310726-60-3. The hemihydrate has a separate CAS, 2050057-56-0, and contains one water molecule per two drug molecules. These forms require different composition and assay checks. The reference identity defines this profile; an unqualified registry name does not establish the solid-state form or water content of a particular material.

CAS number
1310726-60-3
PMDA: anhydrate and hemihydrate identities

Anhydrous reference identity; the CAS of each individual filing has not been independently verified.

Upadacitinib chemical properties

The Upadacitinib formula and reference molecular weight below describe the anhydrous molecule. Hydration changes composition and mass. For a material comparison, request the stated chemical form, water content, assay basis and impurity specification from the relevant manufacturer. Registry packaging fields describe reported pack sizes rather than purchase quantities or current stock.

Molecular formula
C17H19F3N6O
PubChem: Upadacitinib identifiers
Molecular weight
380.4 g/mol
PubChem: Upadacitinib identifiers

Chemical-form and regulatory resources

Use these official references to check Upadacitinib identifiers, distinguish the hemihydrate and interpret the two registries.

Upadacitinib API sourcing questions

What is the Upadacitinib API identity used on this page?

This Upadacitinib profile uses anhydrous free-base CAS 1310726-60-3, formula C17H19F3N6O and PubChem CID 58557659. ABT-494 is a reported synonym. These are reference identifiers for the page, while the registry entries are selected by name and do not individually supply CAS confirmation.

Is Upadacitinib hemihydrate the same chemical form?

Upadacitinib hemihydrate has CAS 2050057-56-0 and includes half a water molecule per drug molecule. The anhydrous reference has CAS 1310726-60-3. Explicit hemihydrate filings are excluded here. Confirm the intended form, water content and assay basis before comparing specifications or requesting a sample.

Which Upadacitinib FDA DMF records are included?

The supplied Q2 2026 list yields 9 Type II records whose subjects match UPADACITINIB after trimming whitespace for selection. Original subject text remains intact. Three intermediate subjects and six hemihydrate subjects are excluded. A Type II designation also covers intermediates, so matching the keyword alone is insufficient.

Does an active Upadacitinib DMF mean FDA approval?

No. FDA A means active and I means inactive. FDA states that DMFs are neither approved nor disapproved. An Upadacitinib listing does not establish supplier qualification, manufacturing-site approval, permission to reference the dossier or current availability. Verify the official record and request the documentation relevant to your application.

How are China CDE Upadacitinib registrations selected?

The supplied export contains 30 registrations named exactly 乌帕替尼. Upadacitinib records retain all eleven source fields, including original enterprise names, packaging and unfilled specifications. Distinct registration numbers are counted separately; several belong to the same reported enterprise. The export does not provide a CAS field to confirm each registration’s chemical form.

What do the CDE A and I codes mean?

For Upadacitinib registrations, CDE codes describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I covers technical review not passed or a registration not yet linked to a formulation. Use the snapshot date and current official record when interpreting either code.

What should I verify before sourcing Upadacitinib API?

Use the Upadacitinib records to identify reported parties and dossier references, then verify the legal entity, manufacturing site, exact chemical form, specification and right to reference the relevant dossier with the company. Request supporting batch and analytical documents for your intended use. A registry listing alone does not establish these points.

What Upadacitinib data can I view before subscribing?

The free Upadacitinib preview shows a limited sample from each registry and provides matching CSV samples. Overview counts describe the complete selected dataset. A subscription enables the remaining available records, search, status filtering and complete CSV exports. It does not provide quotations, supplier qualification or live registry monitoring.

PubChem: Upadacitinib identifiersPMDA: anhydrate and hemihydrate identitiesFDA DMF list: Q2 2026 snapshotNMPA CDE API registry snapshotFDA: Types of Drug Master FilesFDA: Drug Master FilesChina API registration status explained

Data sources

Primary references for chemical identity, registration records and status definitions. Open each source to check its scope and current information.

PubChem: Upadacitinib identifiers

Open source reference

National Center for Biotechnology Information, U.S. National Library of Medicine

Reports the molecular formula, reference molecular weight, anhydrous CAS and ABT-494 synonym for CID 58557659.

View citation evidence

“C17H19F3N6O”

National Center for Biotechnology Information, U.S. National Library of Medicine

Molecular formula in PubChem CID 58557659.

PMDA: anhydrate and hemihydrate identities

Open source reference

Pharmaceuticals and Medical Devices Agency; dossier submitted by AbbVie

The sponsor dossier distinguishes anhydrate CAS 1310726-60-3 from hemihydrate CAS 2050057-56-0 and gives the hydrate composition.

View citation evidence

“1310726-60-3 (anhydrate)”

Pharmaceuticals and Medical Devices Agency; dossier submitted by AbbVie

AbbVie clinical overview hosted by PMDA, section 2.7.1, Table 2.7.1-1, printed page 10 (PDF page 10).

FDA DMF list: Q2 2026 snapshot

Open source reference

U.S. Food and Drug Administration

The selected filings come from the supplied second-quarter workbook, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.

View citation evidence

“UPADACITINIB”

U.S. Food and Drug Administration

Reported subject of the selected Type II records in worksheet 2Q2026-EXCEL; DMF 40344 retains its original trailing space.

FDA: Drug Master Files

Open source reference

U.S. Food and Drug Administration

Explains DMF use and review. A listing or active status does not establish approval of a supplier or product.

View citation evidence

“Are neither approved nor disapproved.”

U.S. Food and Drug Administration

FDA statement about DMFs; their technical contents are reviewed with applications that reference them.

FDA: Types of Drug Master Files

Open source reference

U.S. Food and Drug Administration

Type II is broader than APIs, so the reported subject must also be checked.

View citation evidence

“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”

U.S. Food and Drug Administration

FDA Type II category heading.

NMPA CDE API registry snapshot

Open source reference

Center for Drug Evaluation, National Medical Products Administration

The October 5, 2026 export supplies the name-selected registrations, with original Chinese company names, status codes, packaging, dates and blank fields.

View citation evidence

“乌帕替尼”

Center for Drug Evaluation, National Medical Products Administration

Exact substance name of the selected registrations in the supplied eleven-column CSV.

China API registration status explained

Open source reference

Liaoning Medical Products Administration

Official explanation of A and I, including joint review, qualifying prior approvals and independent API review.

View citation evidence

“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”

Liaoning Medical Products Administration

Regulator explanation published February 18, 2025: I covers technical review not passed or a registration not yet linked to a formulation.

Continue your Upadacitinib API research

Compare Upadacitinib registry names, review codes and chemical-form boundaries using the free samples. Subscribe to search, filter and export the complete available FDA and CDE records for your sourcing review.

Complete data requires an active subscription. Already subscribed? Sign in to access your data.

Report a data issue

Report an Upadacitinib data issue with the page address, registry number and supporting official evidence. APIRFQ support handles data corrections. Contact the relevant company separately about material specifications, dossier access or supply.

Contact data support